Tadashi Nishimura

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 13

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi, Akihiko Yagi, Haruko Saiki, Taro Yasuma, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Corina N D'Alessandro-Gabazza, Esteban C Gabazza, Tetsu Kobayashi
Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors. Cancer medicine 13 (8) (2024)
Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi, Akihiko Yagi, Haruko Saiki, Taro Yasuma, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Corina N D'Alessandro-Gabazza, Esteban C Gabazza, Tetsu Kobayashi
Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors. Cancer medicine 13 (8) (2024)
Tadashi Nishimura, Takumi Fujiwara, Hajime Fujimoto
When and how should next-generation sequencing and comprehensive genomic profiling assays be performed? Cancer science (2024)
Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi, Akihiko Yagi, Haruko Saiki, Taro Yasuma, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Corina N D'Alessandro-Gabazza, Esteban C Gabazza, Tetsu Kobayashi
Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors. Cancer medicine 13 (8) (2024)
Tadashi Nishimura, Takumi Fujiwara, Hajime Fujimoto, Hirotoshi Tarumi, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Masahiro Naito, Yoshinaga Okugawa, Taro Yasuma, Esteban Cesar Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Hidenori Ibata
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma. Thoracic cancer (2023)
Tadashi Nishimura, Takumi Fujiwara, Hajime Fujimoto, Hirotoshi Tarumi, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Masahiro Naito, Yoshinaga Okugawa, Taro Yasuma, Esteban Cesar Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Hidenori Ibata
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma. Thoracic cancer 14 (7) (2023)
Tadashi Nishimura, Takumi Fujiwara, Hajime Fujimoto, Hirotoshi Tarumi, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Masahiro Naito, Yoshinaga Okugawa, Taro Yasuma, Esteban Cesar Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Hidenori Ibata
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma. Thoracic cancer (2023)
Tadashi Nishimura, Takumi Fujiwara, Hajime Fujimoto, Hirotoshi Tarumi, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Masahiro Naito, Yoshinaga Okugawa, Taro Yasuma, Esteban Cesar Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Hidenori Ibata
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma. Thoracic cancer 14 (7) (2023)
Yurie Kogue, Hiroyasu Kobayashi, Yutaka Nakamura, Takatsugu Takano, Chihiro Furuta, Osamu Kawano, Taro Yasuma, Tadashi Nishimura, Corina N D'Alessandro-Gabazza, Hajime Fujimoto, Esteban C Gabazza, Tetsu Kobayashi, Ichiro Fukai
Prognostic Value of CXCL12 in Non-Small Cell Lung Cancer Patients Undergoing Tumor Resection. Pharmaceuticals (Basel, Switzerland) 16 (2) (2023)
Tadashi Nishimura, Takumi Fujiwara, Hajime Fujimoto, Hirotoshi Tarumi, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Masahiro Naito, Yoshinaga Okugawa, Taro Yasuma, Esteban Cesar Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Hidenori Ibata
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma. Thoracic cancer 14 (7) (2023)
Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Akihiko Yagi, Valeria Fridman D'Alessandro, Taro Yasuma, Kazuki Furuhashi, Haruko Saiki, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Corina N D'Alessandro-Gabazza, Esteban C Gabazza, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Tetsu Kobayashi
Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy. Cancers 14 (16) (2022)
Tadashi Nishimura, Hajime Fujimoto, Tomohito Okano, Masahiro Naito, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Taro Yasuma, Corina N D'Alessandro-Gabazza, Yasuhiro Oomoto, Esteban C Gabazza, Tetsu Kobayashi, Hidenori Ibata
Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice? Cancers 14 (12) (2022)
Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Soichi Iwanaka, Ayaka Ohiwa, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N D'Alessandro-Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban Cesar Gabazza, Hidenori Ibata
Second-line therapy with first- or second-generation tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with T790M-negative or unidentified mutation. Thoracic cancer 12 (7) (2021)

Tadashi Nishimura.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Tadashi Nishimura